Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.
Search
All
Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.
The participation of the Blue Forward FundTM, managed by Seventure Partners, and the PSIM fund, managed by Bpifrance on behalf of the French government, confirms the strong...
The company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, reflects enthusiasm for Siolta's...
Maat Pharma announces that the DSMB unanimoulsy recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host Disease...
IDnow, a leading identity proofing platform provider in Europe, has obtained the remote identity verification certification known as PVID (prestataire de verification...
Enterome today announces that the first patient was dosed in the Phase 1/2 'AUDREY' trial evaluating EO4010, the Company's third OncoMimics™ candidate, for the treatment of...
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry...
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, today announces...